Molecular and Cellular Biochemistry

, Volume 340, Issue 1, pp 265–273

Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1

  • Te Liu
  • Fuhui Xu
  • Xiling Du
  • Dongmei Lai
  • Tianjin Liu
  • Yarui Zhao
  • Qin Huang
  • Lizhen Jiang
  • Wenbin Huang
  • Weiwei Cheng
  • Zhixue Liu
Article

DOI: 10.1007/s11010-010-0426-5

Cite this article as:
Liu, T., Xu, F., Du, X. et al. Mol Cell Biochem (2010) 340: 265. doi:10.1007/s11010-010-0426-5

Abstract

Multi-drug resistance is an important element which leads to ineffectiveness of chemotherapeutics. To identify subpopulations of cancerous prostate cells with mutli-drug resistance and cancer stem-cell properties has recently become a major research interest. We identified a subpopulation from the prostate cancer cell line 22RV1, which have high surface expression of both CD117 and ABCG2. We found this subpopulation of cells termed CD117+/ABCG2+ also overexpress stem cells markers such as Nanog, Oct4, Sox2, Nestin, and CD133. These cells are highly prolific and are also resistant to treatment with a variety of chemotherapeutics such as casplatin, paclitaxel, adriamycin, and methotrexate. In addition, CD117+/ABCG2+ cells can readily establish tumors in vivo in a relatively short time. To investigate the mechanism of aggressive tumor growth and drug resistance, we examined the CpG islands on the ABCG2 promoter of CD117+/ABCG2+ cells and found they were remarkably hypomethylated. Furthermore, chromatin immunoprecipitation assays revealed high levels of both histone 3 acetylation and H3K4 trimethylation at the CpG islands on the ABCG2 promoter. Our these data suggest that CD117+/ABCG2+ cells could be reliably sorted from the human prostate cancer cell line 22RV1, and represent a valuable model for studying cancer cell physiology and multi-drug resistance. Furthermore, identification and study of these cells could have a profound impact on selection of individual treatment strategies, clinical outcome, and the design or selection of the next generation of chemotherapeutic agents.

Keywords

Carcinoma-initiating stem-like cellsABCG2Multidrugs resistantEpigenetic modificationCell models

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Te Liu
    • 1
    • 2
  • Fuhui Xu
    • 1
  • Xiling Du
    • 1
  • Dongmei Lai
    • 2
  • Tianjin Liu
    • 3
  • Yarui Zhao
    • 1
  • Qin Huang
    • 3
  • Lizhen Jiang
    • 3
  • Wenbin Huang
    • 1
  • Weiwei Cheng
    • 2
  • Zhixue Liu
    • 1
  1. 1.School of Life Science and TechnologyTongji UniversityShanghaiChina
  2. 2.Center Laboratory, International Peace Maternity and Child Health HospitalShanghai Jiaotong UniversityShanghaiChina
  3. 3.Hehong (Shanghai) Biotechnology LtdShanghaiChina